Global Prostate Cancer Testing Market 2018-2022
About Prostate Cancer Testing
Prostate cancer testing refers to the tests conducted for the detection, localization, grading, and staging of prostate carcinoma. The currently established methods of prostate cancer detection include digital rectal examination (DRE), serum prostate-specific antigen (PSA) tests, and transrectal ultrasound (TRUS)-guided prostate biopsy using a systematic 12-core method.
Technavio’s analysts forecast the global prostate cancer testing market to grow at a CAGR of 10.96% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global prostate cancer testing market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Prostate Cancer Testing Market 2018-2022
Technavio recognizes the following companies as the key players in the global prostate cancer testing market: C. R. Bard, Cook Medical, Danaher, F. Hoffmann-La Roche, MDxHealth, OPKO Health, and Siemens Healthcare.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is increasing focus on biomarker research. The development of biomarkers has accelerated with the recent developments in high throughput technology platforms in proteomics, genomics, and immunology. The manufacturers are focusing on developing prostate cancer biomarkers which can foretell disease aggressiveness and drive better treatment decision
According to the report, one driver in the market is increasing incidence of prostate cancer. The incidence of prostate cancer is increasing worldwide and is the second most common cancer diagnosed in men. It is estimated that every year approximately one million new cases of prostate cancer are diagnosed worldwide.
Further, the report states that one challenge in the market is cost implications associated with prostate cancer diagnosis. The high cost of prostate cancer testing products is limiting their adoption. For instance, 4kscore Test offered by OPKO health costs $595, Prolaris offered by Myriad Genetics costs approximately $3,500, and phi offered by Danaher costs approximately $500.
C. R. Bard, Cook Medical, Danaher, F. Hoffmann-La Roche, MDxHealth, OPKO Health, and Siemens Healthcare.